NASDAQ:LSTA Lisata Therapeutics (LSTA) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free LSTA Stock Alerts $2.66 -0.17 (-6.01%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.63▼$2.9050-Day Range$2.65▼$3.3552-Week Range$1.95▼$4.53Volume6,093 shsAverage Volume13,010 shsMarket Capitalization$22.10 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Lisata Therapeutics alerts: Email Address Lisata Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside463.9% Upside$15.00 Price TargetShort InterestHealthy0.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.08) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector390th out of 907 stocksPharmaceutical Preparations Industry174th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingLisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLisata Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.24% of the float of Lisata Therapeutics has been sold short.Short Interest Ratio / Days to CoverLisata Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lisata Therapeutics has recently decreased by 4.17%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLisata Therapeutics does not currently pay a dividend.Dividend GrowthLisata Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LSTA. Previous Next 2.6 News and Social Media Coverage News SentimentLisata Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lisata Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of Lisata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.94% of the stock of Lisata Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lisata Therapeutics are expected to grow in the coming year, from ($3.08) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lisata Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lisata Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLisata Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Lisata Therapeutics Stock (NASDAQ:LSTA)Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Read More LSTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LSTA Stock News HeadlinesApril 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)April 23, 2024 | finance.yahoo.comLisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumorsApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 23, 2024 | finance.yahoo.comLisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaApril 23, 2024 | globenewswire.comLisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaApril 19, 2024 | americanbankingnews.comLisata Therapeutics (NASDAQ:LSTA) Stock Price Up 2.5%April 11, 2024 | finanznachrichten.deLisata Therapeutics, Inc.: Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of OsteosarcomaApril 9, 2024 | markets.businessinsider.comLisata Receives FDA Orphan Drug Designation For LSTA1 To Treat OsteosarcomaApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 9, 2024 | globenewswire.comLisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of OsteosarcomaApril 3, 2024 | globenewswire.comLisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor EventsMarch 21, 2024 | msn.comLisata gets FDA rare pediatric disease status for lead drugMarch 21, 2024 | markets.businessinsider.comLisata's LSTA1 Gets Rare Pediatric Disease Designation From FDA For OsteosarcomaMarch 21, 2024 | globenewswire.comLisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of OsteosarcomaMarch 15, 2024 | finance.yahoo.comHere's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn SituationMarch 4, 2024 | financialpost.comLisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰMarch 2, 2024 | seekingalpha.comLisata Therapeutics, Inc. (LSTA) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finanznachrichten.deLisata Therapeutics, Inc.: Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 1, 2024 | finance.yahoo.comQ4 2023 Lisata Therapeutics Inc Earnings CallFebruary 29, 2024 | benzinga.comRecap: Lisata Therapeutics Q4 EarningsFebruary 29, 2024 | globenewswire.comLisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | benzinga.comLisata Therapeutics's Earnings OutlookFebruary 22, 2024 | globenewswire.comLisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern TimeFebruary 20, 2024 | finance.yahoo.comLisata Therapeutics to Present at BIO CEO & Investor ConferenceFebruary 20, 2024 | globenewswire.comLisata Therapeutics to Present at BIO CEO & Investor ConferenceJanuary 18, 2024 | msn.comLisata Therapeutics treats first patient in Phase IIa trial of LSTA1 drugSee More Headlines Receive LSTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LSTA CUSIPN/A CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees25Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+463.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.06% Return on Assets-34.52% Debt Debt-to-Equity RatioN/A Current Ratio8.18 Quick Ratio8.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.88 per share Price / Book0.45Miscellaneous Outstanding Shares8,310,000Free Float6,513,000Market Cap$22.10 million OptionableNot Optionable Beta1.04 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. David J. Mazzo B.A. (Hons) (Age 67)B.Sc. (Hons.), M.Sc., Ph.D., President, CEO & Director Comp: $1.16MDr. Kristen K. Buck M.D. (Age 49)Executive VP of R&D and Chief Medical Officer Comp: $938.42kMr. James NiscoVP of Finance & TreasuryMr. Tariq ImamVice President of Business Development & Operations and Corporate CounselMr. Gregory S. BerkinChief Information OfficerMr. John D. MendittoVice President of Investor Relations & Corporate CommunicationsMs. Gail Holler (Age 65)Vice President of Human Resources Dr. William K. Sietsema Ph.D. (Age 68)Vice President of Global Regulatory Affairs Comp: $350.55kMore ExecutivesKey CompetitorsMEI PharmaNASDAQ:MEIPTherapeuticsMDNASDAQ:TXMDSynlogicNASDAQ:SYBXLumos PharmaNASDAQ:LUMOIndaptus TherapeuticsNASDAQ:INDPView All CompetitorsInstitutional OwnershipBML Capital Management LLCBought 14,830 shares on 4/23/2024Ownership: 3.426%BML Capital Management LLCBought 26,000 shares on 1/30/2024Ownership: 3.315%View All Institutional Transactions LSTA Stock Analysis - Frequently Asked Questions Should I buy or sell Lisata Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LSTA shares. View LSTA analyst ratings or view top-rated stocks. What is Lisata Therapeutics' stock price target for 2024? 1 brokers have issued twelve-month target prices for Lisata Therapeutics' stock. Their LSTA share price targets range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 463.9% from the stock's current price. View analysts price targets for LSTA or view top-rated stocks among Wall Street analysts. How have LSTA shares performed in 2024? Lisata Therapeutics' stock was trading at $2.73 at the beginning of the year. Since then, LSTA shares have decreased by 2.6% and is now trading at $2.66. View the best growth stocks for 2024 here. Are investors shorting Lisata Therapeutics? Lisata Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 16,800 shares, an increase of 69.7% from the March 15th total of 9,900 shares. Based on an average daily trading volume, of 13,600 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.3% of the company's stock are sold short. View Lisata Therapeutics' Short Interest. When is Lisata Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LSTA earnings forecast. How were Lisata Therapeutics' earnings last quarter? Lisata Therapeutics, Inc. (NASDAQ:LSTA) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.20. Who are Lisata Therapeutics' major shareholders? Lisata Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (3.43%). How do I buy shares of Lisata Therapeutics? Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LSTA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
